Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail

Keyphrases

• Liposomes 100%
• Cytarabine 100%
• Daunorubicin 100%
• CPX-351 100%
• Newly Diagnosed 100%
• Secondary Acute Myeloid Leukemia (sAML) 100%
• Acute Myeloid Leukemia 66%
• Preclinical Development 33%
• Initial Treatment 33%
• Anthracyclines 33%
• Continuous Infusion 33%
• T-AML 33%
• Overall Survival 33%
• Response Rate 33%
• Recent Introduction 33%
• Mutation Specific 33%
• Liposomal Encapsulation 33%

Medicine and Dentistry

• Cytarabine 100%
• Secondary Acute Myeloid Leukemia 100%
• Liposomal Daunorubicin 100%
• Acute Myeloid Leukemia 100%
• Disease 33%
• Prognostication 33%
• Continuous Infusion 33%
• Overall Survival 33%
• Anthracycline 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Daunorubicin 100%
• Secondary Acute Myeloid Leukemia 100%
• Acute Myeloid Leukemia 100%
• Cytarabine 100%
• Overall Survival 33%
• Disease 33%
• Anthracycline 33%